Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04852822 · ClinicalTrials.gov registry record

Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A clinical trial, sponsored by University of Washington.

Terminated
Registry status
350
Enrollment target

NCT04852822: Clinical Trial study, sponsored by University of Washington.

NCT04852822 is a clinical trial that was terminated before completion, run by University of Washington. The registered enrollment target is 350 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04852822 was terminated before completion, sponsored by University of Washington.

TERMINATED
Registry status
350 participants
Enrollment target

Study Summary

This study evaluates the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer that begin in cells of the immune system. CLL/SLL and the medications used to treat these conditions may change the way vaccines work in a patient's body. The purpose of this study is to find out if patients with CLL/SLL make antibodies, or have an immune response, to the SARS-CoV-2 vaccines. Information gained from this study may help researchers better understand how effective the vaccines work in preventing COVID-19 (coronavirus disease 2019) in patients with CLL and SLL.

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Electronic Health Record Review

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2021-03-18
Est. Completion 2024-07-01
University of Washington

1,048 total trials

Why NCT04852822 stopped before completion

NCT04852822 is an observational study that tracks outcomes without assigning an intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.

NCT04852822 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04852822 about?

NCT04852822 is a clinical study titled "Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". This study evaluates the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer that begin in cells of the immune system. CLL/SLL and the m...

What is the current status of trial NCT04852822?

This trial is currently terminated. The enrollment target is 350 participants. The study started on 2021-03-18. Estimated completion is 2024-07-01.

What interventions are being tested in trial NCT04852822?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Electronic Health Record Review (OTHER).

Who is sponsoring clinical trial NCT04852822?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00900575 · 350 participants · NA

    Cervical Cancer Detection Using Optical Spectroscopy

  • NCT01627821 · 350 participants · NA

    Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study

  • NCT02357654 · 350 participants · Phase 4

    GnRH for Luteal Support in IVF/ICSI/FET Cycles

  • NCT03997370 · 350 participants · Phase 1

    Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04852822, the US trial registry maintained by the National Library of Medicine. NCT04852822 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.